How ADC Design Impacts CMC Development

In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) discuss how the various parts and pieces of an ADC construct may impact CMC planning. For example, novel payloads or linkers will require more de-risking than clinically validated payloads or linkers.